ATE531730T1 - Immunogene hybridpolypeptide mit wirkung gegen obesitas und diese enthaltende impstoffzusammensetzung mit wirkung gegen obesitas - Google Patents

Immunogene hybridpolypeptide mit wirkung gegen obesitas und diese enthaltende impstoffzusammensetzung mit wirkung gegen obesitas

Info

Publication number
ATE531730T1
ATE531730T1 AT05721957T AT05721957T ATE531730T1 AT E531730 T1 ATE531730 T1 AT E531730T1 AT 05721957 T AT05721957 T AT 05721957T AT 05721957 T AT05721957 T AT 05721957T AT E531730 T1 ATE531730 T1 AT E531730T1
Authority
AT
Austria
Prior art keywords
obesitas
vaccine composition
activity
composition containing
containing same
Prior art date
Application number
AT05721957T
Other languages
English (en)
Inventor
Hyo-Joon Kim
Original Assignee
Sj Biomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sj Biomed Inc filed Critical Sj Biomed Inc
Application granted granted Critical
Publication of ATE531730T1 publication Critical patent/ATE531730T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D17/00—Arrangements for circulating cooling fluids; Arrangements for circulating gas, e.g. air, within refrigerated spaces
    • F25D17/04—Arrangements for circulating cooling fluids; Arrangements for circulating gas, e.g. air, within refrigerated spaces for circulating air, e.g. by convection
    • F25D17/06—Arrangements for circulating cooling fluids; Arrangements for circulating gas, e.g. air, within refrigerated spaces for circulating air, e.g. by convection by forced circulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/01—Deodorant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/16—Disinfection, sterilisation or deodorisation of air using physical phenomena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2209/00—Aspects relating to disinfection, sterilisation or deodorisation of air
    • A61L2209/10—Apparatus features
    • A61L2209/12—Lighting means
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D2317/00—Details or arrangements for circulating cooling fluids; Details or arrangements for circulating gas, e.g. air, within refrigerated spaces, not provided for in other groups of this subclass
    • F25D2317/04—Treating air flowing to refrigeration compartments
    • F25D2317/041—Treating air flowing to refrigeration compartments by purification
    • F25D2317/0415—Treating air flowing to refrigeration compartments by purification by deodorizing
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D2317/00—Details or arrangements for circulating cooling fluids; Details or arrangements for circulating gas, e.g. air, within refrigerated spaces, not provided for in other groups of this subclass
    • F25D2317/04—Treating air flowing to refrigeration compartments
    • F25D2317/041—Treating air flowing to refrigeration compartments by purification
    • F25D2317/0417—Treating air flowing to refrigeration compartments by purification using an UV-lamp
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D2317/00—Details or arrangements for circulating cooling fluids; Details or arrangements for circulating gas, e.g. air, within refrigerated spaces, not provided for in other groups of this subclass
    • F25D2317/06—Details or arrangements for circulating cooling fluids; Details or arrangements for circulating gas, e.g. air, within refrigerated spaces, not provided for in other groups of this subclass with forced air circulation
    • F25D2317/068—Details or arrangements for circulating cooling fluids; Details or arrangements for circulating gas, e.g. air, within refrigerated spaces, not provided for in other groups of this subclass with forced air circulation characterised by the fans
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Mechanical Engineering (AREA)
  • Combustion & Propulsion (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Thermal Sciences (AREA)
  • Peptides Or Proteins (AREA)
AT05721957T 2004-03-18 2005-03-18 Immunogene hybridpolypeptide mit wirkung gegen obesitas und diese enthaltende impstoffzusammensetzung mit wirkung gegen obesitas ATE531730T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040018551A KR100639397B1 (ko) 2004-03-18 2004-03-18 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
PCT/KR2005/000784 WO2005087800A1 (en) 2004-03-18 2005-03-18 Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same

Publications (1)

Publication Number Publication Date
ATE531730T1 true ATE531730T1 (de) 2011-11-15

Family

ID=35064517

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05721957T ATE531730T1 (de) 2004-03-18 2005-03-18 Immunogene hybridpolypeptide mit wirkung gegen obesitas und diese enthaltende impstoffzusammensetzung mit wirkung gegen obesitas

Country Status (12)

Country Link
US (1) US7829667B2 (de)
EP (1) EP1756143B1 (de)
JP (1) JP4554672B2 (de)
KR (1) KR100639397B1 (de)
CN (1) CN1956995B (de)
AT (1) ATE531730T1 (de)
AU (1) AU2005222019B2 (de)
BR (1) BRPI0508916A (de)
CA (1) CA2560539C (de)
MX (1) MXPA06010635A (de)
RU (1) RU2341534C2 (de)
WO (1) WO2005087800A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2418005C2 (ru) * 2006-09-25 2011-05-10 ЭсДжей БАЙОМЕД ИНК. Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды
EP3463416A1 (de) 2016-05-31 2019-04-10 CardioVax, LLC Verfahren zur diagnose und behandlung von systemischen lupus erythematodes
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
JP7423554B2 (ja) * 2018-05-30 2024-01-29 ドイチェス クレブスフォルシュンクスツェントルム 予防用及び治療用の組み合わせワクチン
MX2023000904A (es) * 2020-07-22 2023-02-22 3H Bio Co Ltd Un peptido utilizado para agentes inmunoterapeuticos.
WO2022086301A1 (ko) * 2020-10-23 2022-04-28 에스케이바이오사이언스 주식회사 황열 바이러스를 코딩하는 유전물질을 포함하는, 타겟 조직의 크기 또는 부피 축소용 백신 조성물 또는 키트
JP2025513535A (ja) * 2022-04-22 2025-04-24 エスケー バイオサイエンス カンパニー リミテッド ターゲット組織の大きさ又は体積の縮小用組成物、若しくはそれを含むキット
CN121518565B (zh) * 2026-01-15 2026-03-27 苏州大学 水稻OsPBL8基因在增强水稻对稻瘟病菌的抗性中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68920735T2 (de) 1988-03-25 1995-05-24 Mallinckrodt Veterinary Inc Peptide die vom Maul- und Klauenseuchevirus stammen.
ZA932660B (en) * 1992-04-17 1993-10-26 Sankyo Co Derivatives of adipogenesis inhibitory factor, their preparation and their use
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
RU2273645C9 (ru) * 1994-08-17 2006-11-27 Дзе Рокефеллер Юниверсити Полипептид ожирения (ов)(варианты), его аналог (варианты) и слитый белок (варианты), изолированная молекула нуклеиновой кислоты, молекула днк, рекомбинантный вектор клонирования, рекомбинантный вектор экспрессии, фармацевтическая композиция, моноклональное и поликлональное антитело
WO1997024440A1 (en) * 1995-12-27 1997-07-10 Genentech, Inc. Ob protein derivatives having prolonged half-life
US6284533B1 (en) * 1996-05-01 2001-09-04 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
EP1267908B1 (de) * 2000-03-03 2004-05-06 GlaxoSmithKline Biologicals S.A. Impstoff zur behandlung von atherosclerosis
KR100472841B1 (ko) 2000-09-04 2005-03-07 (주)에스제이바이오메드 아포지단백질 비-100의 에피토프에 대한 모조 펩타이드,그들의 연쇄물 또는 변형체와 이들을 함유하는 백신 조성물
CN1231262C (zh) 2000-09-04 2005-12-14 金晓骏 载脂蛋白b－100表位的模拟肽、其多联体和修饰肽,以及含有这些肽的疫苗组合物
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US6954446B2 (en) 2002-06-25 2005-10-11 Motorola, Inc. Multiple mode RF communication device
EP1532172A2 (de) * 2002-08-30 2005-05-25 Glaxo Group Limited Immunogene zusammensetzung die ein il-13 element und t zellepitope behält, und deren therapeutische verwendung

Also Published As

Publication number Publication date
CN1956995B (zh) 2011-03-30
MXPA06010635A (es) 2007-03-26
KR20050093280A (ko) 2005-09-23
EP1756143A4 (de) 2010-10-06
RU2341534C2 (ru) 2008-12-20
US7829667B2 (en) 2010-11-09
JP4554672B2 (ja) 2010-09-29
CN1956995A (zh) 2007-05-02
EP1756143B1 (de) 2011-11-02
AU2005222019B2 (en) 2008-01-31
BRPI0508916A (pt) 2007-08-14
CA2560539A1 (en) 2005-09-22
US20100240575A1 (en) 2010-09-23
JP2008500813A (ja) 2008-01-17
EP1756143A1 (de) 2007-02-28
RU2006136786A (ru) 2008-04-27
WO2005087800A1 (en) 2005-09-22
CA2560539C (en) 2011-08-09
KR100639397B1 (ko) 2006-10-26
AU2005222019A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
NO20063026L (no) Antistoffer
NZ707439A (en) Modified factor ix polypeptides and uses thereof
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
RU2011106744A (ru) Инсулин, стабилизированный галогеном
ATE277947T1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
MXPA03002145A (es) Genes de la proteina homologa inmunodominante de 28 kilodaltones de ehrlichia canis y usos.
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
DK1844150T3 (da) Rekombinant ekspression af proteiner i en to-kædet form med disulfidbroer
WO2007091030A3 (en) Peptide sequences and compositions
ATE530672T1 (de) Rekombinante adenoviren mit affen-adenovirus proteinen und verwendung davon.
EA201291362A1 (ru) Слитый белок против злокачественных новообразований
EA036805B8 (ru) Белок cd24 для подавления ответа хозяина на damp
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
PE20121722A1 (es) Polipeptido de fusion contra tumor inducido por virus eb y mutante de colicina ia
ATE531730T1 (de) Immunogene hybridpolypeptide mit wirkung gegen obesitas und diese enthaltende impstoffzusammensetzung mit wirkung gegen obesitas
ATE555800T1 (de) Zusammensetzung mit dem polyprotein ns3/ns4 und dem polypeptid ns5b von hcv, expressionsvektoren mit den entsprechenden nukleinsäuresequenzen und ihre therapeutische verwendung
ATE477272T1 (de) Verwendung von stefin a als gerüstprotein
DE60118359D1 (de) Humanische pellino-polypeptide
DE60323634D1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
DE602005018615D1 (de) Schen polypeptiden und deren verwendung als impfstoffe und in der immuntherapie
RU2009115688A (ru) Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды
RU2005126236A (ru) Фьюжн-белок для подавления цервикального рака
NZ603611A (en) Insulin-like growth factor 1 receptor binding peptides
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon